Robotic Minimally Invasive Benign Hysterectomy Post-market Clinical Study With the DEXTER Robotic System
Condition(s) studied
Investigational drug(s) / intervention(s)
benign hysterectomy: Robotic-assisted and laparoscopic hysterectomy for benign disease with the DEXTER robotic surgery system.
Study summary
The purpose of this post-market, observational study is to collect real-world data under anticipated conditions of use that demonstrates that the device performs as intended (accurate, precise control of surgical instruments) in patients undergoing robotic-assisted and laparoscopic hysterectomy for benign disease.
Eligibility
Primary outcome measure(s)
- Primary safety outcome — up to 42 days after surgery
Occurrence of Clavien-Dindo grades III-V adverse events - Primary efficacy outcome — Intraoperative
Successful completion of the DEXTER-assisted procedure, i.e. free of any conversion to an open or fully laparoscopic surgical approach
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Cypress surgery center | Wichita | Kansas | |
| Memorial Hermann-Texas Medical Center - UT Health Houston | Houston | Texas |
More Distalmotion SA trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07746531 on ClinicalTrials.gov ↗ ← All trials in the USA